Intensive therapy in newly diagnosed type 2 diabetes: Results of a 6-year randomized trial

Journal of Investigative Medicine

Volumn 62, Issue 4, 2014, Pages 676-686

  Harrison, Lindsay B ^a   Adams Huet, Beverley ^a,b   Li, Xilong ^b   Raskin, Philip ^a   Lingvay, Ildiko ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Glycemic control; Hypoglycemia; Insulin resistance; Insulin treatment; Mixed meal challenge test; Quality of life; Triple oral hypoglycemic therapy; Type 2 diabetes; Weight gain; cell function

Indexed keywords

ALANINE AMINOTRANSFERASE; C PEPTIDE; CREATININE; GLIBENCLAMIDE; HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN ASPART; METFORMIN; PIOGLITAZONE; GLUCOSE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARDIOVASCULAR RISK; CELL FUNCTION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN SENSITIVITY; INSULIN TREATMENT; INTENSIVE CARE; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PATIENT COMPLIANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; WEIGHT REDUCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CREATININE BLOOD LEVEL; DIET RESTRICTION; FOLLOW UP; HEMOGLOBIN BLOOD LEVEL; HUMAN CELL; INSULIN RELEASE; MIDDLE AGED; PROVOCATION TEST; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HYPERGLYCEMIA; METABOLISM; PATHOLOGY; QUESTIONNAIRE; RISK FACTOR; TREATMENT FAILURE;

ADULT; AREA UNDER CURVE; BIOMARKERS; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; QUALITY OF LIFE; RISK FACTORS; SURVEYS AND QUESTIONNAIRES; TREATMENT FAILURE;

EID: 84902134777     PISSN: 17088267     EISSN: 17088267     Source Type: Journal    
DOI: 10.2310/JIM.0000000000000068     Document Type: Article

References (25)

1. El-Assaad W, Buteau J, Peyot ML, et al. Saturated fatty acids synergize with elevated glucose to cause pancreatic beta-cell death. Endocrinology. 2003;144(9):4154-4163. (Pubitemid 37088771)
2. Steffes MW, Sibley S, Jackson M, et al. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26(3):832-836. (Pubitemid 36929351)
3. ORIGIN Trial Investigators, Gerstein HC, Bosch J, et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med. 2012;367(4):319-328.
4. Ilkova H, Glaser B, Tunçkale A, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment. Diabetes Care. 1997;20(9):1353-1356. (Pubitemid 27366805)
5. Li Y, Xu W, Liao Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004;27(11):2597-2602. (Pubitemid 39441457)
6. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27(5):1028-1032. (Pubitemid 38579760)
7. Weng J, Li Y, XuW, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371(9626):1753-1760.
8. Chen HS, Wu TE, Jap TS, et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care. 2008;31(10):1927-1932.
9. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355(23):2427-2443. (Pubitemid 44903747)
10. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281(21):2005-2012. (Pubitemid 29254858)
11. Harrison LB, Adams-Huet B, Raskin P, et al. A-cell function preservation after 3.5 years of intensive diabetes therapy. Diabetes Care. 2012;35(7):1406-1412.
12. Lingvay I, Kaloyanova PF, Adams-Huet B, et al. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med. 2007;55(2):62-68. (Pubitemid 46723943)
13. Lingvay I, Legendre JL, Kaloyanova PF, et al. Insulin-based versus triple oral therapy for newly diagnosed type 2 diabetes: which is better? Diabetes Care. 2009;32(10):1789-1795.
14. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care. 1999;22(9):1462-1470. (Pubitemid 29418240)
15. Radaelli T, Farrell KA, Huston-Presley L, et al. Estimates of insulin sensitivity using glucose and C-Peptide from the hyperglycemia and adverse pregnancy outcome glucose tolerance test. Diabetes Care. 2010;33(3):490-494.
16. Kahn SE, Prigeon RL, McCulloch DK, et al. Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function. Diabetes. 1993;42(11):1663-1672.
17. Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent-onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011;96(1):159-167.
18. TODAY Study Group, Zeitler P, Hirst K, et al. A clinical trial to maintain glycemic control in youth with type 2 diabetes. N Engl J Med. 2012;366(24):2247-2256.
19. TODAY Study Group. Effects of metformin, metformin plus rosiglitazone, and metformin plus lifestyle on insulin sensitivity and A-cell function in TODAY. Diabetes Care. 2013;36(6):1749-1757.
20. Kahn SE, Lachin JM, Zinman B, et al. Effects of rosiglitazone, glyburide, and metformin on A-cell function and insulin sensitivity in ADOPT. Diabetes. 2011;60(5):1552-1560.
21. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364-1379. Erratum in: Diabetes Care. 2013;36(2):490.
22. Yki-Järvinen H. Thiazolidinediones. N Engl J Med. 2004;351(11):1106-1118.
23. DeFronzo RA, Triplitt C, Qu Y, et al. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010;33(5):951-957.
24. Preumont V, Hermans MP, Brichard S, et al. Six-month exenatide improves HOMA hyperbolic product in type 2 diabetic patients mostly by enhancing beta-cell function rather than insulin sensitivity. Diabetes Metab. 2010;36(4):293-298.
25. Abdul-Ghani M, Puckett C, Adams J, et al. Initial triple combination therapy is superior to stepwise add-on conventional therapy in newly diagnosed T2DM. Diabetes. 2013;62(Supplement 1):A1-A98.